Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing therapies for rare diseases. The company uses its proprietary TransCon technology to create long-acting prodrugs. Despite its innovative approach, Ascendis faces challenges in capital efficiency, as indicated by its financial metrics.
Ascendis Pharma's ROIC is -18.95%, which is significantly lower than its WACC of 5.88%. This negative ROIC suggests that the company is not generating sufficient returns to cover its cost of capital. This is a red flag for investors, as it implies that the company is not using its capital effectively to generate profits.
In comparison, argenx SE (ARGX) has a ROIC of 7.68% and a WACC of 4.55%, resulting in a ROIC to WACC ratio of 1.69. This indicates that argenx is generating returns well above its cost of capital, making it more efficient in capital utilization compared to Ascendis.
Apellis Pharmaceuticals, Inc. (APLS) also demonstrates efficient capital use with a ROIC of 8.81% and a WACC of 5.31%, leading to a ROIC to WACC ratio of 1.66. This suggests that Apellis, like argenx, is effectively using its capital to generate returns.
On the other hand, Blueprint Medicines Corporation (BPMC) shares a similar challenge with Ascendis, having a negative ROIC of -13.09% against a WACC of 8.26%. This indicates inefficiencies in capital utilization, similar to Ascendis, and highlights the importance of efficient capital management in the biopharmaceutical industry.
